Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2004

01-09-2004

Does Subjective Burden of Early Breast Cancer and its Treatment Affect Immune Measures During Adjuvant Therapy?

Authors: Marzio E.E. Sabbioni, Jürg Bernhard, Hans-Peter Siegrist, Shu-Fang Hsu Schmitz, Monica Castiglione Gertsch, Beat Thürlimann, Hervé Bonnefoi, Lucien Perey, Richard Herrmann, Aron Goldhirsch, Christoph Hürny

Published in: Breast Cancer Research and Treatment | Issue 1/2004

Login to get access
Metadata
Title
Does Subjective Burden of Early Breast Cancer and its Treatment Affect Immune Measures During Adjuvant Therapy?
Authors
Marzio E.E. Sabbioni
Jürg Bernhard
Hans-Peter Siegrist
Shu-Fang Hsu Schmitz
Monica Castiglione Gertsch
Beat Thürlimann
Hervé Bonnefoi
Lucien Perey
Richard Herrmann
Aron Goldhirsch
Christoph Hürny
Publication date
01-09-2004
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2004
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/B:BREA.0000041584.53863.a7

Other articles of this Issue 1/2004

Breast Cancer Research and Treatment 1/2004 Go to the issue

OriginalPaper

Possible Association Between c-erbB-2 and Human Papillomavirus-16 in Breast Cancer Patients

OriginalPaper

Biomarker investigations from the ATAC trial: the role of TA01

OriginalPaper

Failure of High Risk Women to Produce Nipple Aspirate Fluid Does Not Exclude Detection of Cytologic Atypia in Random Periareolar Fine Needle Aspiration Specimens

OriginalPaper

EGFR and EGFRvIII Expression in Primary Breast Cancer and Cell Lines

OriginalPaper

The Experimental Antitumor Agents Phortress and Doxorubicin are Equiactive Against Human-Derived Breast Carcinoma Xenograft Models

OriginalPaper

Genetic Variants of the Sulfotransferase 1A1 and Breast Cancer Risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits